Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Phase 2
Terminated
NCT05581589
| Condition | Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Washington |
|---|
| Status | Terminated |
|---|
| Enrollment | 4 participants |
|---|
| Interventions | Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan |
|---|
| Start date | Jun 15, 2023 |
|---|
| Completion date | Oct 15, 2024 |
|---|
| Results posted | Apr 27, 2026 |
|---|
Summary
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Pathologic Complete Response (pCR Defined as ypT0N0)
At radical cystectomy (Radical cystectomy is expected to occur within 2-6 weeks after the last neoadjuvant trial therapy dose) · Participants
| Treatment (Sacituzumab Govitecan) | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.